Emirati Biomedical Innovation Secures International Patent for Advanced Cardiac Research Technology
A leading UAE-based biotechnology and advanced laboratory organisation has announced a significant intellectual property achievement following the submission of an international patent application under the Patent Cooperation Treaty (PCT). The patent pertains to an innovative technology poised to advance cardiac research and regenerative medicine.
The patent application, titled “Scalable Generation of Human Induced Pluripotent Stem Cell-Derived Cardiac Organoids,” marks a notable milestone for biomedical innovation originating from the United Arab Emirates. This development underscores the organisation’s dedication to developing practical scientific solutions with global potential.
The innovation has already received a positive examination report from the Korean Intellectual Property Office, confirming its compliance with essential patentability criteria, including novelty, inventive step, and industrial applicability.
In essence, the technology introduces a scalable method for producing cardiac organoids, which are laboratory-grown models mimicking human heart tissue characteristics. These models are crucial for studying heart disease progression, understanding cellular responses to various conditions, and evaluating potential treatments within a controlled research setting. By enabling the consistent and large-scale production of these organoids, the technology is expected to facilitate faster and more efficient research in areas such as cardiovascular disease, drug development, personalised medicine, and regenerative therapies.
The CEO of the organisation emphasised that this patent milestone reflects the ambition for Emirati science to make meaningful contributions to the future of global healthcare. The stated goal is to develop innovations that address critical medical challenges, thereby strengthening the UAE’s position in advanced biomedical research and creating solutions that could enhance the lives of future generations. It is important to note that this achievement provides an advanced scientific platform for researchers, rather than representing a direct treatment or cure for heart disease.
The innovation resulted from an international scientific collaboration between the UAE-based entity and the Marga and Walter Boll Laboratory in Cologne, Germany, involving Prof. Kurt Pfannkuche and Dr. Sarkawt Hamad. This partnership combined specialist expertise in stem cell science, cardiac tissue modelling, and regenerative medicine, illustrating the importance of international collaboration in translating laboratory discoveries into practical technologies. The underlying scientific research supporting this innovation has been published in the peer-reviewed journal Theranostics.
As the UAE continues its strategic investment in advanced healthcare, life sciences, and medical research, this intellectual property achievement highlights the increasing contribution of UAE-based institutions to global scientific progress and biomedical innovation. The organisation provides commercial services and products across stem cell banking, genomics, genetic testing, consumer genomics, and regenerative medicine, aiming to advance personalised healthcare and contribute to the future of life sciences within the UAE and beyond.